Caribou Biosciences (CRBU) Competitors $1.80 -0.03 (-1.64%) Closing price 04:00 PM EasternExtended Trading$1.84 +0.04 (+2.22%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRBU vs. MAZE, RZLT, TRML, TYRA, GOSS, PROK, DNA, BCAX, SNDL, and SEPNShould you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Maze Therapeutics (MAZE), Rezolute (RZLT), Tourmaline Bio (TRML), Tyra Biosciences (TYRA), Gossamer Bio (GOSS), ProKidney (PROK), Ginkgo Bioworks (DNA), Bicara Therapeutics (BCAX), SNDL (SNDL), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Caribou Biosciences vs. Its Competitors Maze Therapeutics Rezolute Tourmaline Bio Tyra Biosciences Gossamer Bio ProKidney Ginkgo Bioworks Bicara Therapeutics SNDL Septerna Caribou Biosciences (NASDAQ:CRBU) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends. Do analysts recommend CRBU or MAZE? Caribou Biosciences currently has a consensus price target of $6.67, indicating a potential upside of 270.37%. Maze Therapeutics has a consensus price target of $32.67, indicating a potential upside of 39.24%. Given Caribou Biosciences' higher probable upside, equities analysts plainly believe Caribou Biosciences is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has higher valuation and earnings, CRBU or MAZE? Maze Therapeutics has higher revenue and earnings than Caribou Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$9.99M16.78-$149.10M-$1.78-1.01Maze Therapeutics$167.50M6.14$52.23MN/AN/A Does the media prefer CRBU or MAZE? In the previous week, Maze Therapeutics had 30 more articles in the media than Caribou Biosciences. MarketBeat recorded 32 mentions for Maze Therapeutics and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.82 beat Maze Therapeutics' score of 0.72 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Maze Therapeutics 10 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is CRBU or MAZE more profitable? Maze Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,800.93%. Maze Therapeutics' return on equity of 0.00% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,800.93% -62.35% -49.65% Maze Therapeutics N/A N/A N/A Do insiders & institutionals have more ownership in CRBU or MAZE? 77.5% of Caribou Biosciences shares are owned by institutional investors. 9.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryMaze Therapeutics beats Caribou Biosciences on 9 of the 14 factors compared between the two stocks. Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBU vs. The Competition Export to ExcelMetricCaribou BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$170.42M$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-1.018.1457.1222.76Price / Sales16.78446.35528.74123.58Price / CashN/A45.4037.1760.46Price / Book0.659.6212.796.29Net Income-$149.10M-$53.28M$3.28B$270.51M7 Day Performance-2.17%0.31%0.22%2.15%1 Month Performance-9.09%4.58%4.61%6.35%1 Year Performance-11.33%9.24%68.33%25.48% Caribou Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBUCaribou Biosciences2.8477 of 5 stars$1.80-1.6%$6.67+270.4%-13.7%$170.42M$9.99M-1.01100MAZEMaze Therapeutics3.3604 of 5 stars$14.97-5.7%$26.33+75.9%N/A$696.35M$167.50M0.00121Analyst ForecastInsider TradeGap DownRZLTRezolute2.7314 of 5 stars$7.95-0.6%$12.50+57.2%+42.3%$695.97MN/A-6.9140News CoverageUpcoming EarningsTRMLTourmaline Bio0.8522 of 5 stars$30.18+12.9%$50.14+66.1%+147.3%$687.00MN/A-8.8044Analyst DowngradeHigh Trading VolumeTYRATyra Biosciences2.4099 of 5 stars$12.13-4.1%$31.43+159.1%-42.0%$674.21MN/A-6.8120Positive NewsAnalyst UpgradeGOSSGossamer Bio3.9599 of 5 stars$2.66-9.5%$8.50+219.5%+245.1%$668.50M$114.70M-4.29180News CoverageAnalyst UpgradeGap UpPROKProKidney3.4969 of 5 stars$2.16-4.0%$6.25+189.4%+2.5%$662.14M$80K-3.793DNAGinkgo Bioworks1.6578 of 5 stars$11.19+0.3%$9.50-15.1%+62.5%$660.08M$227.04M-1.91640Positive NewsBCAXBicara Therapeutics2.0234 of 5 stars$12.29+1.9%$32.25+162.4%N/A$658.03MN/A-3.8832Positive NewsSNDLSNDL3.6504 of 5 stars$2.39-3.6%$4.50+88.3%+20.8%$651.68M$671.81M-8.852,516SEPNSepterna1.6199 of 5 stars$14.67+1.7%$26.75+82.3%N/A$643.36M$1.08M-1.45N/AAnalyst Downgrade Related Companies and Tools Related Companies Maze Therapeutics Competitors Rezolute Competitors Tourmaline Bio Competitors Tyra Biosciences Competitors Gossamer Bio Competitors ProKidney Competitors Ginkgo Bioworks Competitors Bicara Therapeutics Competitors SNDL Competitors Septerna Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBU) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
